Content |
Development of BioTechnologies (RBT) is a Russian developer of various vaccines.
History
2023: Attraction of RUB 155 mln of investments
On July 13, 2023, it became known about the investment of 155 million rubles in the RBT company. The vaccine developer received funds during a closed placement on the investment platform of the resident "Skolkovo Rounds."
According to the press service of Skolkovo, as part of this financing, the startup hoped to attract up to 160 million rubles. It is noted that the placement took place along the upper border, with a re-signature. The amount of applications from investors wishing to take part in the first investment round of the company reached more than 251 million rubles.
The money received will be used to expand the portfolio of vaccines developed by the company and complete clinical trials of the influenza vaccine. In March 2023, Investment Director of the Human Stem Cell Institute "(ISCH; owns RBT) Dmitry Krasotkin said that Biotechnologies Development plans to hold a public offering of shares in 2025-2026.
IPO is planned when positive dynamics of key financial indicators, favorable industry prospects, market growth and projected high demand for shares are achieved. The company can also start paying dividends of up to 75% of net income. According to the company's own estimate, due to license payments, its revenue may exceed 1 billion rubles by 2027.
 | The placement was successful thanks to the ISKCH ecosystem and the support of investors from Skolkovo. This is a good example of the fact that in Russia investors have an interest in biotech. And biotech for its development is able to attract investments in the venture capital market. Investments are planned to be directed to expanding the RBT development portfolio, - said Igor Krasilnikov, commenting on raising funds during a closed placement on the Rounds investment platform.[1] |  |
2020: Attracting 47.6 million rubles of investments
On December 15, 2020, the Human Stem Cell Institute (ISKCH) announced the investment of 47.6 million rubles in the BioTechnologies Development company.
ISKCH Director General Artur Isaev explained the investment decision by the fact that, according to forecasts, coronavirus (COVID-19) infection and the need for re-vaccination will be important not only within the current pandemic, but also in subsequent years. At the same time, the company invests in platforms and technologies that will create vaccines in other areas significant for healthcare, he said.
| | The prevention of infectious diseases with vaccines will obviously now become a more relevant and demanded request from health care and society. Effective and long-term safe vaccines with good performance at cost and scalability of production will be needed, "said Artur Isaev, commenting on the deal with RBT. | |
By mid-December 2020, the coronavirus vaccine is being developed by RBT in partnership with Betuvax, a member of the ISCH group and specializing in biotechnology research and development. BioTechnologies Development plans to introduce a platform for the development of antiviral candidate vaccines based on recombinant proteins on nanoparticles. Previously, according to the company, the platform showed a high safety profile and the required level of immunogenicity and efficacy in preclinical studies. The ISCH stressed that the project is being carried out by a team of scientists with good experience and competencies in the field of vaccine development.
RBT plans to participate in the development of vaccines for COVID-19, influenza and human papillomavirus.[2]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |